General Info

Alnylam Pharmaceuticals is a biopharmaceutical company. The company develops novel therapeutics based on the biological breakthrough known as ribonucleic acid interference. The company applies ribonucleic acid interference to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies. This discovery enables the creation of a broad new class of human therapeutics. Alnylam Pharmaceuticals maintains partnerships with leading pharmaceutical and medical technology companies to drive further developments and capabilities. Major alliances include Merck, Medtronic and Novartis. Alnylam Pharmaceuticals, founded in 2002, maintains global headquarters in Cambridge, Mass., and has an additional operating unit in Kulmbach, Germany.